2-[(E)-2-(4-butoxyphenyl)ethenyl]quinazolin-4(3H)-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-[(E)-2-(4-butoxyphenyl)ethenyl]quinazolin-4(3H)-one
• 英文别名: 2-[(E)-2-(4-butoxyphenyl)ethenyl]-3H-quinazolin-4-one
• 化学式: C₂₀H₂₀N₂O₂
• 分子量: 320.391
• InChiKey: BDDZIRMHQLTYKG-JLHYYAGUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  50.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-甲基-4(3H)-喹唑酮 、 4-丁氧基苯甲醛 在 溶剂黄146 作用下， 以 水 、 乙酸酐 为溶剂， 反应 16.0h， 以20%的产率得到2-[(E)-2-(4-butoxyphenyl)ethenyl]quinazolin-4(3H)-one
  参考文献：
  名称：

  The p53 stabilizing agent CP-31398 and multi-kinase inhibitors. Designing, synthesizing and screening of styrylquinazoline series

  摘要：

  Quinazoline derivatives constitute a large family of small-molecule inhibitors of tyrosine kinases. In the current study, the p53 protein reactivator CP-31398 was tested against a panel of kinases on the assumption that it was structurally similar to other active inhibitors. Although it was found to be active in the enzyme-based assay, this compound did not block the proliferation of cancer cells at a feasible concentration level. The styrylquinazoline was used to design new structures that might be potential multitarget inhibitors. Subsequently, a series of compounds was obtained and characterized. Their inhibitory activity in a panel of tyrosine kinases had an antiproliferative effect against several cancer cell lines that have different expression levels of those proteins. The mode of protein interaction was tested for the most active compound in docking experiments. (C) 2018 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2018.12.012

文献信息

• The p53 stabilizing agent CP-31398 and multi-kinase inhibitors. Designing, synthesizing and screening of styrylquinazoline series
  作者：Jacek Mularski、Katarzyna Malarz、Marcin Pacholczyk、Robert Musiol

  DOI：10.1016/j.ejmech.2018.12.012

  日期：2019.2

  Quinazoline derivatives constitute a large family of small-molecule inhibitors of tyrosine kinases. In the current study, the p53 protein reactivator CP-31398 was tested against a panel of kinases on the assumption that it was structurally similar to other active inhibitors. Although it was found to be active in the enzyme-based assay, this compound did not block the proliferation of cancer cells at a feasible concentration level. The styrylquinazoline was used to design new structures that might be potential multitarget inhibitors. Subsequently, a series of compounds was obtained and characterized. Their inhibitory activity in a panel of tyrosine kinases had an antiproliferative effect against several cancer cell lines that have different expression levels of those proteins. The mode of protein interaction was tested for the most active compound in docking experiments. (C) 2018 Elsevier Masson SAS. All rights reserved.